Dr. Karen Reckamp, MD
Claim this profileTorrance Memorial Physician Network - Cancer Care
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
8 reported clinical trials
13 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
MET positive
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
MET positive
Affiliated Hospitals
Clinical Trials Karen Reckamp, MD is currently running
Osimertinib + Carotuximab
for Lung Cancer
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.
Recruiting2 awards Phase 115 criteria
Bevacizumab + Chemoimmunotherapy + Atezolizumab
for Small Cell Lung Cancer
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.
Recruiting1 award Phase 211 criteria
More about Karen Reckamp, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Karen Reckamp, MD has experience with
- Pembrolizumab
- Ramucirumab
- Carotuximab
- Osimertinib
- Chemotherapy
- Atezolizumab
Breakdown of trials Karen Reckamp, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Liver Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karen Reckamp, MD specialize in?
Karen Reckamp, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Karen Reckamp, MD currently recruiting for clinical trials?
Yes, Karen Reckamp, MD is currently recruiting for 5 clinical trials in Torrance California. If you're interested in participating, you should apply.
Are there any treatments that Karen Reckamp, MD has studied deeply?
Yes, Karen Reckamp, MD has studied treatments such as Pembrolizumab, Ramucirumab, Carotuximab.
What is the best way to schedule an appointment with Karen Reckamp, MD?
Apply for one of the trials that Karen Reckamp, MD is conducting.
What is the office address of Karen Reckamp, MD?
The office of Karen Reckamp, MD is located at: Torrance Memorial Physician Network - Cancer Care, Torrance, California 90505 United States. This is the address for their practice at the Torrance Memorial Physician Network - Cancer Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.